IBB

From Frenzy Capital
Jump to navigation Jump to search

Symbol Name Rank Change Headline Date
ALT Altimmune Inc 7.02 4.5304 The outlook and analysis of Altimmune Inc. (ALT)’s stock - MZP News 11/29/2022, 08:16:00
ALT Altimmune Inc 7.02 4.5304 Are needle-free COVID vaccines our way out of the pandemic? - STL.News 11/27/2022, 12:19:26
ALT Altimmune Inc 7.02 4.5304 Altimmune, Inc. (NASDAQ:ALT) is expected to earn ($1.82) per share in fiscal year 2022. - Best Stocks 11/24/2022, 03:48:45
ALT Altimmune Inc 7.02 4.5304 Seasonal Influenza Market to Proliferate at a CAGR of 6.1% During the Forecast Period (2022-2032), Assesses DelveInsight - PR Newswire UK 11/23/2022, 10:30:00
ALT Altimmune Inc 7.02 4.5304 Altimmune, Inc. (NASDAQ:ALT) Expected to Post FY2022 Earnings of ($1.82) Per Share - MarketBeat 11/23/2022, 06:33:26
AMGN AMGEN Inc. 1.83 -0.7501 3 rumors pushing around stocks today By Investing.com - Investing.com India 11/29/2022, 17:53:15
AMGN AMGEN Inc. 1.83 -0.7501 Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch 11/29/2022, 17:32:00
AMGN AMGEN Inc. 1.83 -0.7501 Amazon Seizes Sales Opportunity With $8.25 Billion of Bonds - Yahoo Finance 11/29/2022, 17:09:27
AMGN AMGEN Inc. 1.83 -0.7501 Noteworthy Tuesday Option Activity: AMGN, MDGL, NVCR - Nasdaq 11/29/2022, 16:51:00
AMGN AMGEN Inc. 1.83 -0.7501 Horizon Therapeutics fields buyout interest from Amgen, J&J and Sanofi - Reuters 11/29/2022, 16:44:00
ALLO Allogene Therapeutics Inc 1.76 -7.0175 Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform - GlobeNewswire 11/29/2022, 15:30:12
ALLO Allogene Therapeutics Inc 1.76 -7.0175 Nestlé reconsiders peanut allergy program two years after $2.6B buyout - Endpoints News 11/29/2022, 12:48:00
ALLO Allogene Therapeutics Inc 1.76 -7.0175 Boehringer Ingelheim buys CD38 drug; Merck bets on machine learning in antibody design - Endpoints News 11/29/2022, 10:57:00
ALLO Allogene Therapeutics Inc 1.76 -7.0175 Viatris withdraws accelerated approval for topical antimicrobial 24 years later - Endpoints News 11/29/2022, 10:53:00
ALLO Allogene Therapeutics Inc 1.76 -7.0175 Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca - Endpoints News 11/29/2022, 08:00:00
MDGL Madrigal Pharmaceuticals Inc 1.66 4.8362 Noteworthy Tuesday Option Activity: AMGN, MDGL, NVCR - Nasdaq 11/29/2022, 16:51:00
MDGL Madrigal Pharmaceuticals Inc 1.66 4.8362 The Liver Fibrosis Market Size in the 7MM was USD 2225 million in 2021 - Digital Journal 11/29/2022, 16:11:05
MDGL Madrigal Pharmaceuticals Inc 1.66 4.8362 Akero Therapeutics: What Is Making The Stock Tick (NASDAQ:AKRO) - Seeking Alpha 11/23/2022, 11:01:00
MDGL Madrigal Pharmaceuticals Inc 1.66 4.8362 Notable Friday Option Activity: MDGL, SAVA, MSTR - Nasdaq 11/18/2022, 03:00:00
MDGL Madrigal Pharmaceuticals Inc 1.66 4.8362 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Short Interest Up 17.4% in October - MarketBeat 11/14/2022, 03:00:00
ANNX Annexon Inc 1.64 -3.3854 Amyotrophic Lateral Sclerosis Clinical Trials, Pipeline Assessment Insights into the Current Therapies, Emer - openPR 11/29/2022, 06:15:00
ANNX Annexon Inc 1.64 -3.3854 New affordable housing groundbreaking at Gladstone School building in Hazelwood - CBS Pittsburgh 11/21/2022, 15:57:00
ANNX Annexon Inc 1.64 -3.3854 We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate - Yahoo Finance 11/21/2022, 06:13:02
ANNX Annexon Inc 1.64 -3.3854 Iveric Bio Inc: ISEE Stock's Eye Watering Rise - Value the Markets 11/18/2022, 03:00:00
ANNX Annexon Inc 1.64 -3.3854 Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com 11/17/2022, 16:02:02
FGEN FibroGen Inc 1.52 1.4235 Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors - Yahoo Finance 11/29/2022, 08:00:00
FGEN FibroGen Inc 1.52 1.4235 Global Aesthetic Injectables Market Key Players, Growth Opportunities, Future Challenges, Application, CAGR, Forecast by 2029 - Digital Journal 11/29/2022, 07:51:29
FGEN FibroGen Inc 1.52 1.4235 Myelodysplastic Syndrome (MDS) Treatment Market See Incredible Growth 2022-2028 Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd. - Digital Journal 11/29/2022, 04:30:56
FGEN FibroGen Inc 1.52 1.4235 Where Does FibroGen Inc (FGEN) Stock Fall in the Biotechnology Field After It Has Fallen -4.54% This Week? - InvestorsObserver 11/28/2022, 14:25:35
FGEN FibroGen Inc 1.52 1.4235 Duchenne Muscular Dystrophy Market to Reach $2.1 Billion, Globally, by 2031 at 4.7% CAGR: Allied Market Research - PR Newswire UK 11/28/2022, 07:18:00
ENTA Enanta Pharmaceuticals Inc 1.52 2.018 Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term - Simply Wall St 11/25/2022, 05:22:56
ENTA Enanta Pharmaceuticals Inc 1.52 2.018 Enanta Pharmaceuticals Full Year 2022 Earnings: Revenues Disappoint - Simply Wall St 11/23/2022, 05:23:49
ENTA Enanta Pharmaceuticals Inc 1.52 2.018 Enanta Pharmaceuticals, Inc. (ENTA) Q4 2022 Earnings Call Transcript - Seeking Alpha 11/21/2022, 18:10:00
ENTA Enanta Pharmaceuticals Inc 1.52 2.018 Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates - Zacks Investment Research 11/21/2022, 16:31:34
ENTA Enanta Pharmaceuticals Inc 1.52 2.018 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET - Business Wire 11/21/2022, 16:02:00
CDXS Codexis Inc. 2.89 -0.5952 CODEXIS, INC. : Costs Associated with Exit or Disposal Activities (form 8-K) - Marketscreener.com 11/29/2022, 16:10:08
CDXS Codexis Inc. 2.89 -0.5952 Codexis Provides Update on Prioritized Corporate Strategy - GlobeNewswire 11/29/2022, 16:05:00
CDXS Codexis Inc. 2.89 -0.5952 Synthetic Biology Market is anticipated to expand at a CAGR of 19.2% from 2023 to 2032 insightSLIC - PharmiWeb.com 11/29/2022, 10:21:24
CDXS Codexis Inc. 2.89 -0.5952 Enzyme Substrates Market is Evaluated USD 14.40 billion by 2021 and Excepted to Reach USD 18.07 billion by 2028 – Skegness Siren - Skegness Siren 11/25/2022, 04:49:17
CDXS Codexis Inc. 2.89 -0.5952 Biofuel Enzyme Market to Grow at a Stayed 7.34% CAGR with Huge Profits by 2028 DSM, BASF SE, DuPont., AB Enzy - openPR 11/23/2022, 06:10:00
NRXP NRX Pharmaceuticals Inc 2.85 10.4 Is NRX Pharmaceuticals Inc (NRXP) a Stock to Watch After Gaining 44.00% This Week? - InvestorsObserver 11/29/2022, 12:10:46
NRXP NRX Pharmaceuticals Inc 2.85 10.4 Why Shares Of Chinese Companies Are Trading Higher? Here Are 45 Stocks Moving In Tuesday’s Mid-Day Sessio - Benzinga 11/29/2022, 11:47:48
NRXP NRX Pharmaceuticals Inc 2.85 10.4 NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - MyChesCo 11/22/2022, 23:00:05
NRXP NRX Pharmaceuticals Inc 2.85 10.4 Where Does NRX Pharmaceuticals Inc (NRXP) Stock Fall in the Biotechnology Field After It Has Risen 14.44% This Week? - InvestorsObserver 11/21/2022, 17:56:47
NRXP NRX Pharmaceuticals Inc 2.85 10.4 NurExone announces FDA discussion as they bring hope to millions of spinal cord injury patients (TSXV: NRX) (FSE: J90) - EIN News 11/21/2022, 04:37:00
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.76 1.865 Lysosomal Storage Diseases Market 2022 Growth Factors, Opportunities, Ongoing Trends and Key Players 2032 - Digital Journal 11/28/2022, 21:27:58
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.76 1.865 Costing $3.5M, first hemophilia B gene therapy wins FDA approval - FiercePharma 11/23/2022, 10:49:56
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.76 1.865 BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A - Investor Relations : BioMarin 11/23/2022, 08:34:16
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.76 1.865 NICE advises against Merck's Lagevrio, AZ's Evusheld, 3 other COVID drugs - FiercePharma 11/16/2022, 10:50:54
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.76 1.865 GSK, J&J, and AZ top 2022 drug access index - FiercePharma 11/16/2022, 03:00:00
GERN Geron Corp. 0.69 5.2402 Myelodysplastic Syndrome (MDS) Treatment Market See Incredible Growth 2022-2028 Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd. - Digital Journal 11/29/2022, 04:30:56
GERN Geron Corp. 0.69 5.2402 Hygienic Night Pants Market Size 2022, Top Countries Segmented by Applications and Geography Trends – Skegness Siren - Skegness Siren 11/28/2022, 00:31:29
GERN Geron Corp. 0.69 5.2402 [2022-2030 Human Embryonic Stem Cells (Hesc) Market will Witness Substantial Growth With in-detailed Competit - openPR] 11/23/2022, 08:02:00
GERN Geron Corp. 0.69 5.2402 No JuJu Smith-Schuster or Mecole Hardman for Chiefs? Worked out OK as others stepped up - Kansas City Star 11/23/2022, 08:00:00
GERN Geron Corp. 0.69 5.2402 Should You Add Geron Corporation (GERN) Stock to Your Portfolio Friday? - InvestorsObserver 11/18/2022, 12:52:03
FREQ Frequency Therapeutics Inc 0.69 4.7619 Funding Roundup: Akeyless, Boost Security, CG Oncology, FogPharma, Kyte, Ordergroove, PayZen, Swell Energy, Vizit, WEKA, WorkJam, And Others - Pulse 2.0 11/29/2022, 12:57:00
FREQ Frequency Therapeutics Inc 0.69 4.7619 Nestlé reconsiders peanut allergy program two years after $2.6B buyout - Endpoints News 11/29/2022, 12:48:00
FREQ Frequency Therapeutics Inc 0.69 4.7619 SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Frequency Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors - Longview News-Journal 11/29/2022, 11:05:00
FREQ Frequency Therapeutics Inc 0.69 4.7619 Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting - Yahoo Finance 11/29/2022, 07:30:00
FREQ Frequency Therapeutics Inc 0.69 4.7619 Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease - Yahoo Finance 11/29/2022, 07:00:00
PBYI Puma Biotechnology Inc 0.69 3.8549 Is Puma Biotechnology Inc (PBYI) Stock Over or Undervalued? - InvestorsObserver 11/28/2022, 11:56:19
PBYI Puma Biotechnology Inc 0.69 3.8549 Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday By Benzinga - Investing.com UK 11/28/2022, 06:10:00
PBYI Puma Biotechnology Inc 0.69 3.8549 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product Type (Monotherapy, Combination Therapy), Application (Breast Cancer, Gastric Cancer, Ovarian Cancer, Others), and Geography – Global Trends & Forecasts to 2019-202 - Skegness Siren 11/26/2022, 01:35:29
PBYI Puma Biotechnology Inc 0.69 3.8549 Healthcare Stocks on the Move Friday: EUDA, PKBO, CGTX, NUTX, CHEK, NMTC, XGN, PBYI - InvestorsObserver 11/25/2022, 14:20:25
PBYI Puma Biotechnology Inc 0.69 3.8549 Puma Biotechnology Inc (PBYI) Stock: Do Analysts Think You Should Sell? - InvestorsObserver 11/23/2022, 15:38:46
KMPH KemPharm Inc 0.63 -0.4283 KemPharm Announces Appointment of Christopher Posner as New Independent Director - Yahoo Finance 11/29/2022, 07:30:00
KMPH KemPharm Inc 0.63 -0.4283 Imago stock soars on $1.35B Merck buyout - BioWorld Online 11/21/2022, 12:00:00
KMPH KemPharm Inc 0.63 -0.4283 KemPharm, Inc. Forecasted to Post FY2023 Earnings of ($0.37) Per Share (NASDAQ:KMPH) - MarketBeat 11/21/2022, 02:36:47
KMPH KemPharm Inc 0.63 -0.4283 Analysts Have Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue Estimates By 11% - Yahoo Finance UK 11/20/2022, 07:33:47
KMPH KemPharm Inc 0.63 -0.4283 KemPharm (NASDAQ:KMPH) Upgraded by StockNews.com to "Hold" - MarketBeat 11/19/2022, 03:00:00
NVCR NovoCure Ltd 0.6 6.1376 Noteworthy Tuesday Option Activity: AMGN, MDGL, NVCR - Nasdaq 11/29/2022, 16:51:00
NVCR NovoCure Ltd 0.6 6.1376 Teck Resources taps insider Crystal Prystai for CFO - Yahoo Finance 11/29/2022, 13:50:05
NVCR NovoCure Ltd 0.6 6.1376 Is Novocure Ltd (NVCR) a Stock to Watch After Losing -0.27% This Week? - InvestorsObserver 11/29/2022, 12:00:41
NVCR NovoCure Ltd 0.6 6.1376 After Record Cyber Monday Sales, Analysts Upgrade or Downgrade Affirm, Roku, UPS and More - 24/7 Wall St. 11/29/2022, 11:52:25
NVCR NovoCure Ltd 0.6 6.1376 FedEx To Rally Over 25%? Here Are 10 Other Price Target Changes For Tuesday By Benzinga - Investing.com UK 11/29/2022, 08:40:00
QURE uniQure N.V. 0.5 -2.0864 Other news to note for Nov. 29, 2022 - BioWorld Online 11/29/2022, 17:41:50
QURE uniQure N.V. 0.5 -2.0864 UniQure NV Says Preclinical Data Support AMT-260 Gene Therapy's Safety, Tolerability - Marketscreener.com 11/29/2022, 15:33:03
QURE uniQure N.V. 0.5 -2.0864 BMS Terminates 2015 Gene Therapy Pact with uniQure - BioSpace 11/29/2022, 15:21:32
QURE uniQure N.V. 0.5 -2.0864 Dermavant launches first streaming commercial for Vtama - FiercePharma 11/29/2022, 15:20:00
QURE uniQure N.V. 0.5 -2.0864 Where Will Uniqure NV (QURE) Stock Go Next After It Has Risen 21.37% in a Week? - InvestorsObserver 11/29/2022, 14:51:45
IMVT Immunovant Inc 0.49 -7.9851 Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat 11/29/2022, 03:15:33
IMVT Immunovant Inc 0.49 -7.9851 Are Medical Stocks Lagging BioVie (BIVI) This Year? - Nasdaq 11/25/2022, 09:40:00
IMVT Immunovant Inc 0.49 -7.9851 Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How - Zacks Investment Research 11/17/2022, 03:00:00
IMVT Immunovant Inc 0.49 -7.9851 Is it Time to Dump Immunovant Inc (IMVT) Stock After it Has Gained 4.43% in a Week? - InvestorsObserver 11/08/2022, 12:40:23
IMVT Immunovant Inc 0.49 -7.9851 Wells Fargo Adjusts Price Target on Immunovant to $10 From $7, Maintains Equal-Weight Rating - Marketscreener.com 11/08/2022, 12:01:02
ACRS Aclaris Therapeutics Inc 0.48 0 Astrazeneca paying up to $320M to acquire individualized TCR T-cell therapy developer Neogene - BioWorld Online 11/29/2022, 12:00:00
ACRS Aclaris Therapeutics Inc 0.48 0 Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China - GlobeNewswire 11/29/2022, 07:00:00
ACRS Aclaris Therapeutics Inc 0.48 0 Androgenetic Alopecia Treatment Market Value Projected to Expand by 2030 Histogen Inc, Cipla Limited, Aclaris Therapeutics - Digital Journal 11/28/2022, 09:56:20
ACRS Aclaris Therapeutics Inc 0.48 0 Alopecia Treatment Market Research Report 2022 – Size, Share, Emerging Trends, Historic Analysis, Industry Growth Factors, Forecast to 2028 Aclaris Therapeutics, Inc., Fagron, Follicum AB, Cipla - Digital Journal 11/23/2022, 06:35:38
ACRS Aclaris Therapeutics Inc 0.48 0 Aclaris Therapeutics Announces Key Leadership Transitions - GlobeNewswire 11/22/2022, 16:01:00
IONS Ionis Pharmaceuticals Inc 0.37 -3.8681 Relative Strength Alert For Ionis Pharmaceuticals - Nasdaq 11/29/2022, 16:29:00
IONS Ionis Pharmaceuticals Inc 0.37 -3.8681 Is Ionis Pharmaceuticals Inc (IONS) a Good Buy in the Biotechnology Industry? - InvestorsObserver 11/29/2022, 12:39:33
IONS Ionis Pharmaceuticals Inc 0.37 -3.8681 Transcript : Ionis Pharmaceuticals, Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM - Marketscreener.com 11/29/2022, 10:00:00
IONS Ionis Pharmaceuticals Inc 0.37 -3.8681 U.S. Transthyretin Amyloidosis Treatment Market Size will Grow Profitably in upcoming Estimation year 2028 Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc. - Digital Journal 11/29/2022, 04:30:56
IONS Ionis Pharmaceuticals Inc 0.37 -3.8681 Propulsion of Thalassemia Pipeline as Novel and Extensive 25+ Therapies Likely to Enter in the Treatment Domain DelveInsight - Yahoo Finance 11/28/2022, 13:00:00
ABCM Abcam - ADR (Sponsored) 0.37 -9.1286 Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy–induced toxicities - Science 11/09/2022, 03:00:00
ABCM Abcam - ADR (Sponsored) 0.37 -9.1286 The 7 Best Stocks Under $15 to Buy Now - InvestorPlace 11/08/2022, 03:00:00
ABCM Abcam - ADR (Sponsored) 0.37 -9.1286 AIM Delisting – Abcam plc - Abcam plc 10/17/2022, 02:28:49
ABCM Abcam - ADR (Sponsored) 0.37 -9.1286 Interim results for the period ended 30 June 2022 – Abcam plc - Abcam plc 06/30/2022, 03:00:00
ABCM Abcam - ADR (Sponsored) 0.37 -9.1286 Appointment of Vice President of Investor Relations – Abcam plc - Abcam plc 06/27/2022, 03:00:00
SGEN Seagen Inc 0.26 -3.1513 Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J - Bloomberg 11/29/2022, 17:30:04
SGEN Seagen Inc 0.26 -3.1513 Roche Withdraws Tecentriq's Frontline Bladder Cancer Indication, Ceding Market To Keytruda - Scrip 11/29/2022, 17:25:16
SGEN Seagen Inc 0.26 -3.1513 Incyte Corp. stock falls Tuesday, still outperforms market - MarketWatch 11/29/2022, 17:09:00
SGEN Seagen Inc 0.26 -3.1513 The Global Duodenoscopes Market is Predicted to Surge at a CAGR of 5.2% by 2027, Assesses DelveInsight - GlobeNewswire 11/29/2022, 13:00:00
SGEN Seagen Inc 0.26 -3.1513 Catalent pauses work on unfinished UK biologics plant as it resolves regulatory woes elsewhere - FiercePharma 11/29/2022, 09:01:10
CRBU Caribou Biosciences Inc 0.94 -1.5222 Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy - GlobeNewswire 11/29/2022, 09:00:00
CRBU Caribou Biosciences Inc 0.94 -1.5222 Emerging Trends in CRISPR-Based Therapeutics Market To Witness Highest Demand, Register Healthy Growth With Detail Analysis 2029 Caribou Biosciences, Addgene, CRISPR THERAPEUTICS - Digital Journal 11/25/2022, 05:21:56
CRBU Caribou Biosciences Inc 0.94 -1.5222 Advanced Genomics Market Research Report 2022: Key Disruptive Forces to Transform Health and Wellness - Yahoo Finance 11/23/2022, 06:55:00
CRBU Caribou Biosciences Inc 0.94 -1.5222 CARIBOU BIOSCIENCES, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/21/2022, 09:04:09
CRBU Caribou Biosciences Inc 0.94 -1.5222 Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma - Yahoo Finance 11/21/2022, 09:00:00
FATE Fate Therapeutics Inc 0.25 2.7518 Gene therapy R&D market is projected to grow at a CAGR of 30.1% by 2032: Visiongain Reports Ltd - Benzinga 11/29/2022, 12:29:07
FATE Fate Therapeutics Inc 0.25 2.7518 Cell Regeneration Medicine Market is Booming and Indicating a Significant Growth Rate With Top players To 2030 – AstraZeneca plc, Astellas Pharma Inc - Digital Journal 11/29/2022, 07:47:03
FATE Fate Therapeutics Inc 0.25 2.7518 CAR T Cell Therapy Market See Incredible Growth 2022-2028 Novartis AG, McKinsey & Company, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Amgen Inc. - Digital Journal 11/29/2022, 04:30:56
FATE Fate Therapeutics Inc 0.25 2.7518 Androgenetic Alopecia Treatment Market Value Projected to Expand by 2030 Histogen Inc, Cipla Limited, Aclaris Therapeutics - Digital Journal 11/28/2022, 09:56:20
FATE Fate Therapeutics Inc 0.25 2.7518 Cell Reprogramming Market Size Value Projected to Touch Around USD 618.00 Million by 2030, at 8.0% CAGR Growth: Polaris Market Research - Yahoo Finance 11/28/2022, 09:30:00
LYEL Lyell Immunopharma Inc 0.92 -0.9662 Is C4 Therapeutics Inc (CCCC) a Stock to Watch After Losing -16.53% This Week? - InvestorsObserver 11/29/2022, 14:52:39
LYEL Lyell Immunopharma Inc 0.92 -0.9662 What is the Market's View on Lyell Immunopharma Inc (LYEL) Stock's Price and Volume Trends Tuesday? - InvestorsObserver 11/29/2022, 14:51:45
LYEL Lyell Immunopharma Inc 0.92 -0.9662 AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy - Scrip 11/29/2022, 12:37:43
LYEL Lyell Immunopharma Inc 0.92 -0.9662 Is Lyell Immunopharma Inc (LYEL) a Winner in the Biotechnology Industry? - InvestorsObserver 11/23/2022, 13:59:29
LYEL Lyell Immunopharma Inc 0.92 -0.9662 Deerfield Management Joins $178 Million Series D For FogPharma - citybiz 11/22/2022, 00:31:17
EDIT Editas Medicine Inc 0.25 1.2158 Propulsion of Thalassemia Pipeline as Novel and Extensive 25+ Therapies Likely to Enter in the Treatment Domain DelveInsight - Yahoo Finance 11/28/2022, 13:00:00
EDIT Editas Medicine Inc 0.25 1.2158 Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why - Zacks Investment Research 11/28/2022, 12:32:23
EDIT Editas Medicine Inc 0.25 1.2158 Leber Congenital Amaurosis Market Size, Share Trends, Demand, Application, Type and Growth by 2029 - Digital Journal 11/28/2022, 08:37:11
EDIT Editas Medicine Inc 0.25 1.2158 Should You Accumulate Editas Medicine Inc (EDIT) Stock Friday? - InvestorsObserver 11/25/2022, 14:11:41
EDIT Editas Medicine Inc 0.25 1.2158 CRISPR Technology Market Sees Promising Growth, Future Strategic Planning, and Forecast to 2029 Thermo Fisher Scientific, GenScript Biotech Corporation - Digital Journal 11/25/2022, 05:16:21
ALKS Alkermes plc 0.25 0.2086 CSRWire - Alkermes Supporting Local Communities - CSRwire.com 11/29/2022, 12:46:41
ALKS Alkermes plc 0.25 0.2086 Stress Management Supplements Market with Amid new technological factors - Digital Journal 11/28/2022, 11:33:39
ALKS Alkermes plc 0.25 0.2086 Magnetoencephalograph Market to Register Impressive Expansion of USD 393.91 Million with Excellent CAGR Of 4.90% by 2029 - Digital Journal 11/28/2022, 10:50:30
ALKS Alkermes plc 0.25 0.2086 Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032: Visiongain Reports Ltd - Yahoo Finance 11/25/2022, 11:34:00
ALKS Alkermes plc 0.25 0.2086 How Alkermes (ALKS) Stock Stands Out in a Strong Industry - Nasdaq 11/23/2022, 08:40:00
BCRX Biocryst Pharmaceuticals Inc. 0.25 0.0816 Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Future Business Opportunities 2022-2028 Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals - Digital Journal 11/29/2022, 04:55:08
BCRX Biocryst Pharmaceuticals Inc. 0.25 0.0816 Is BioCryst Pharmaceuticals Inc (BCRX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver 11/28/2022, 11:44:11
BCRX Biocryst Pharmaceuticals Inc. 0.25 0.0816 BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health - GuruFocus.com 11/28/2022, 08:01:50
BCRX Biocryst Pharmaceuticals Inc. 0.25 0.0816 2022-11-28 NDAQ:BCRX Press Release BioCryst Pharmaceuticals Inc. - Stockhouse 11/28/2022, 07:07:05
BCRX Biocryst Pharmaceuticals Inc. 0.25 0.0816 BioCryst Pharma (BCRX) Announces Approval of ORLADEYO by the Israeli Ministry of Health - StreetInsider.com 11/28/2022, 07:05:25
PTCT PTC Therapeutics Inc 0.25 -1.6057 Philanthropy - Orange County Business Journal 11/29/2022, 16:22:17
PTCT PTC Therapeutics Inc 0.25 -1.6057 Amyotrophic Lateral Sclerosis Clinical Trials, Pipeline Assessment Insights into the Current Therapies, Emer - openPR 11/29/2022, 06:15:00
PTCT PTC Therapeutics Inc 0.25 -1.6057 Friedreich's Ataxia Market will generate new growth opportunities 2022-2030 Reata Pharmaceuticals, Inc., Retrotope Inc., Minoryx, PTC Therapeutics - Digital Journal 11/29/2022, 04:55:08
PTCT PTC Therapeutics Inc 0.25 -1.6057 Rezo Therapeutics, Prosper Marketplace score $75M venture rounds - Silicon Valley Business Journal - The Business Journals 11/28/2022, 15:28:00
PTCT PTC Therapeutics Inc 0.25 -1.6057 Becker Muscular Dystrophy Pipeline Assessment, 2022 Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Companies - Digital Journal 11/28/2022, 11:33:39
ATHA Athira Pharma Inc 0.24 1.0563 Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD Conference - GlobeNewswire 11/29/2022, 11:00:00
ATHA Athira Pharma Inc 0.24 1.0563 Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium - Marketscreener.com 11/29/2022, 10:09:20
ATHA Athira Pharma Inc 0.24 1.0563 Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND - Marketscreener.com 11/28/2022, 07:01:02
ATHA Athira Pharma Inc 0.24 1.0563 Athira Pharma, Inc. (NASDAQ:ATHA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat 11/20/2022, 01:10:55
ATHA Athira Pharma Inc 0.24 1.0563 ATHIRA PHARMA, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/18/2022, 16:09:10
NVAX Novavax, Inc. 0.24 0.9615 Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch 11/29/2022, 17:24:00
NVAX Novavax, Inc. 0.24 0.9615 World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults - PR Newswire 11/29/2022, 08:48:00
NVAX Novavax, Inc. 0.24 0.9615 Shionogi applies for COVID-19 vaccine approval, 1st as Japan-made - Kyodo News Plus 11/24/2022, 02:40:10
NVAX Novavax, Inc. 0.24 0.9615 Seasonal Influenza Market to Proliferate at a CAGR of 6.1% During the Forecast Period (2022-2032), Assesses DelveInsight - Yahoo Finance 11/23/2022, 10:30:00
NVAX Novavax, Inc. 0.24 0.9615 COVID-19 Clinical Trials Market Size Predicted to Increase at a Positive CAGR INOVIO Pharmaceuticals, AbbVie Inc., BioNTech SE, Novavax, Takeda - Digital Journal 11/23/2022, 08:10:04
GILD Gilead Sciences, Inc. 0.24 0.4694 Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch 11/29/2022, 17:32:00
GILD Gilead Sciences, Inc. 0.24 0.4694 Gilead Sciences Inc. stock rises Tuesday, outperforms market - MarketWatch 11/29/2022, 17:03:00
GILD Gilead Sciences, Inc. 0.24 0.4694 Transcript : Gilead Sciences, Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Nov-29-2022 01:00 PM - Marketscreener.com 11/29/2022, 13:00:00
GILD Gilead Sciences, Inc. 0.24 0.4694 AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy - Scrip 11/29/2022, 12:37:43
GILD Gilead Sciences, Inc. 0.24 0.4694 Gilead Sciences Says EC Okays Low-Dose Tablet, Indication Extension for Biktarvy to Treat HIV in Pediatric Populations - Marketscreener.com 11/29/2022, 10:29:03
MIRM Mirum Pharmaceuticals Inc 0.24 -6.9173 Full-Life wants more, acquires New Jersey biotech in efforts to dominate radiopharmaceutical R&D - FierceBiotech 11/29/2022, 11:14:15
MIRM Mirum Pharmaceuticals Inc 0.24 -6.9173 Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Analyst Downgrade - MarketBeat 11/29/2022, 10:47:56
MIRM Mirum Pharmaceuticals Inc 0.24 -6.9173 BigHat, cherry-picking opportunities amid stormy market, pens pact with Merck & Co. - FierceBiotech 11/29/2022, 08:05:06
MIRM Mirum Pharmaceuticals Inc 0.24 -6.9173 Mirum Pharmaceuticals Provides Development Program Updates - Business Wire 11/29/2022, 07:30:00
MIRM Mirum Pharmaceuticals Inc 0.24 -6.9173 AstraZeneca inks $200M solid tumor TCR cell therapy buyout - FierceBiotech 11/29/2022, 06:40:00
ALLK Allakos Inc 0.24 8.0163 Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology - GlobeNewswire 11/29/2022, 07:02:00
ALLK Allakos Inc 0.24 8.0163 HC Wainwright Weighs in on Allakos Inc.'s FY2022 Earnings (NASDAQ:ALLK) - MarketBeat 11/28/2022, 01:18:18
ALLK Allakos Inc 0.24 8.0163 Allergic Conjunctivitis Market to Grow Positively at a Paltry During the Study Period (2019–2032), Assesses DelveInsight - Digital Journal 11/22/2022, 06:40:20
ALLK Allakos Inc 0.24 8.0163 Do Analysts Agree Friday on Allakos Inc (ALLK) Stock's Target Price? - InvestorsObserver 11/11/2022, 13:58:06
ALLK Allakos Inc 0.24 8.0163 Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells Communications Biology - Nature.com 11/11/2022, 12:24:19
AVIR Atea Pharmaceuticals Inc 0.24 -0.4376 Atea Pharmaceuticals Says It Dosed First Patient in Phase 3 Trial of Bemnifosbuvir to Treat COVID-19 MarketScreener - Marketscreener.com 11/29/2022, 09:41:02
AVIR Atea Pharmaceuticals Inc 0.24 -0.4376 Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19 - Yahoo Finance 11/29/2022, 07:00:00
AVIR Atea Pharmaceuticals Inc 0.24 -0.4376 Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference - Yahoo Finance 11/22/2022, 07:00:00
AVIR Atea Pharmaceuticals Inc 0.24 -0.4376 COVID-19 Oral Medicine Market Size to surpass 10.5%+ CAGR By 2028 Pfizer Inc., Merck & Co., Novartis AG, Mol - openPR 11/21/2022, 01:04:00
AVIR Atea Pharmaceuticals Inc 0.24 -0.4376 Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 42% loss from investing in the stock a year ago - Yahoo Finance Australia 11/19/2022, 09:46:07
BNTX BioNTech SE - ADR 0.2 0.8236 Should You Hold Immunic Inc (IMUX) in Biotechnology Industry? - InvestorsObserver 11/29/2022, 11:19:19
BNTX BioNTech SE - ADR 0.2 0.8236 How Will the Market React to BioNTech SE - ADR (BNTX) Stock Getting a Bullish Rating - InvestorsObserver 11/29/2022, 11:06:38
BNTX BioNTech SE - ADR 0.2 0.8236 Weekly Upgrades and Downgrades - InvestorPlace 11/28/2022, 14:42:50
BNTX BioNTech SE - ADR 0.2 0.8236 PFE: 1 High-Dividend Stock to Add to Your Portfolio if You Haven't Already - StockNews.com 11/28/2022, 13:40:30
BNTX BioNTech SE - ADR 0.2 0.8236 Should You Accumulate BioNTech SE - ADR (BNTX) Stock Monday? - InvestorsObserver 11/28/2022, 11:51:26
NKTR Nektar Therapeutics 0.14 -6.129 Mirum blames enrollment woes for halting phase 2 trial for pregnancy liver disorder - FierceBiotech 11/29/2022, 09:56:03
NKTR Nektar Therapeutics 0.14 -6.129 Dual drug nanoparticle could curb chemo resistance - FierceBiotech 11/28/2022, 15:37:30
NKTR Nektar Therapeutics 0.14 -6.129 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:35:00
NKTR Nektar Therapeutics 0.14 -6.129 Master and PhD programs in pharmaceutical sciences underway Binghamton News - Binghamton 11/28/2022, 14:49:56
NKTR Nektar Therapeutics 0.14 -6.129 Tapping mRNA to develop elusive universal flu vaccine - FierceBiotech 11/28/2022, 12:43:00
LPTX Leap Therapeutics Inc 0.13 0.1815 Merck Announces First-Quarter 2023 Dividend - Investing News Network 11/29/2022, 11:58:43
LPTX Leap Therapeutics Inc 0.13 0.1815 Interim Data from Ambrx's Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium - Investing News Network 11/29/2022, 08:35:12
LPTX Leap Therapeutics Inc 0.13 0.1815 Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2022 Earnings Call Transcript - Seeking Alpha 11/28/2022, 20:44:00
LPTX Leap Therapeutics Inc 0.13 0.1815 Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer - GlobeNewswire 11/28/2022, 08:00:00
LPTX Leap Therapeutics Inc 0.13 0.1815 Austin lab space in short supply - The Business Journals 11/24/2022, 21:36:00
CARA Cara Therapeutics Inc 0.13 -0.9883 KemPharm Announces Appointment of Christopher Posner as New Independent Director - Cara Therapeutics (NAS - Benzinga 11/29/2022, 07:30:00
CARA Cara Therapeutics Inc 0.13 -0.9883 Neutral On Cara Therapeutics Stock (NASDAQ:CARA) - Seeking Alpha 11/26/2022, 01:32:00
CARA Cara Therapeutics Inc 0.13 -0.9883 The global atopic dermatitis treatment market is expected to grow at a CAGR of 15.20% during 2022-2027 - Yahoo Finance 11/22/2022, 09:04:00
CARA Cara Therapeutics Inc 0.13 -0.9883 Christopher Posner, CEO of Cara Therapeutics, Inc. (NASDAQ:CARA), sells 14,470 shares. - Best Stocks 11/20/2022, 02:53:35
CARA Cara Therapeutics Inc 0.13 -0.9883 Bain Capital Life Sciences Discloses Position in CARA / Cara Therapeutics - Nasdaq 11/19/2022, 20:29:00
ARGX Argen X SE - ADR 0.13 -0.3377 Rising COVID Cases in China, Plunging Oil Prices Drag European Equities Lower in Monday Trading - Marketscreener.com 11/21/2022, 11:29:02
ARGX Argen X SE - ADR 0.13 -0.3377 European ADRs Move Lower in Wednesday Trading - InvestorsObserver 11/09/2022, 11:10:18
ARGX Argen X SE - ADR 0.13 -0.3377 European ADRs Move Higher in Friday Trading - InvestorsObserver 11/04/2022, 12:11:13
ARGX Argen X SE - ADR 0.13 -0.3377 Universe Pharmaceuticals Inc (UPC) Up 5.05% in Premarket Trading - InvestorsObserver 10/25/2022, 06:53:45
ARGX Argen X SE - ADR 0.13 -0.3377 argenx SE - ADR (ARGX) has risen 2.91% in a Week, Should You Buy? - InvestorsObserver 10/20/2022, 13:13:01
AKBA Akebia Therapeutics Inc. 0.13 0 Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal - FierceBiotech 11/28/2022, 10:53:00
AKBA Akebia Therapeutics Inc. 0.13 0 AKBA INVESTOR NOTICE: ROSEN, G - GuruFocus.com 11/28/2022, 06:06:25
AKBA Akebia Therapeutics Inc. 0.13 0 AKBA LAWSUIT ALERT: Levi & Kor - GuruFocus.com 11/27/2022, 15:51:29
AKBA Akebia Therapeutics Inc. 0.13 0 Familial Chylomicronemia Syndrome Therapeutics Market by Product Type (Dietary Supplements Familial Chylomicronemia Syndrome Therapeutics, Gene Therapy Familial Chylomicronemia Syndrome Therapeutics), Application (Hospital Pharmacies, Retail - Skegness Siren 11/27/2022, 05:17:02
AKBA Akebia Therapeutics Inc. 0.13 0 Study estimates the lifetime benefit of combination therapy in patients with kidney disease without diabetes - EurekAlert 11/22/2022, 21:00:43
MRTX Mirati Therapeutics Inc 0.12 -1.7456 Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations - Yahoo Finance 11/29/2022, 08:00:00
MRTX Mirati Therapeutics Inc 0.12 -1.7456 6 biggest deal reports this week: Manchester United open to selling the club By Investing.com - Investing.com 11/26/2022, 17:02:00
MRTX Mirati Therapeutics Inc 0.12 -1.7456 Seasonal Influenza Market to Proliferate at a CAGR of 6.1% During the Forecast Period (2022-2032), Assesses DelveInsight - Yahoo Finance 11/23/2022, 10:30:00
MRTX Mirati Therapeutics Inc 0.12 -1.7456 Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday - Agilen - Benzinga 11/23/2022, 05:25:59
MRTX Mirati Therapeutics Inc 0.12 -1.7456 Cancer Drugmaker Mirati Draws Fresh Takeover Interest - Bloomberg 11/22/2022, 15:17:55
CCCC C4 Therapeutics Inc 0.12 0.6289 Is C4 Therapeutics Inc (CCCC) a Stock to Watch After Losing -16.53% This Week? - InvestorsObserver 11/29/2022, 14:52:39
CCCC C4 Therapeutics Inc 0.12 0.6289 Prothena nets more cash from Novo Nordisk; Khondrion fails to hit endpoint - Endpoints News 11/25/2022, 15:27:42
CCCC C4 Therapeutics Inc 0.12 0.6289 Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday’s Mid-Day Session - - Benzinga 11/25/2022, 12:01:57
CCCC C4 Therapeutics Inc 0.12 0.6289 C4 Therapeutics Inc (CCCC) has fallen -17.08% in a Week, Should You Sell? - InvestorsObserver 11/25/2022, 11:42:58
CCCC C4 Therapeutics Inc 0.12 0.6289 US Stocks Mixed On Black Friday; Dow Rises Over 100 Points - Check-Cap (NASDAQ:CHEK), C4 Therapeutics (NA - Benzinga 11/25/2022, 10:06:54
KDNY Chinook Therapeutics Inc 0.12 0.3467 Proteinuria Therapeutics Market Present Scenario and the Growth Prospects 2022 – 2028 GlaxoSmithKline plc - EIN News 11/29/2022, 07:09:00
KDNY Chinook Therapeutics Inc 0.12 0.3467 Primary Hyperoxaluria Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Primary Hyperoxaluria Pipeline Landscape - Digital Journal 11/25/2022, 12:02:57
KDNY Chinook Therapeutics Inc 0.12 0.3467 2022 Polycystic Kidney Disease Drugs in Development Report: Featuring Angion Biomedica, ATLAS Molecular Pharma, Bristol-Myers Squibb and Camurus Among Others - ResearchAndMarkets.com - WV News 11/25/2022, 06:48:39
KDNY Chinook Therapeutics Inc 0.12 0.3467 Chinook Therapeutics to Presen - GuruFocus.com 11/23/2022, 03:02:20
KDNY Chinook Therapeutics Inc 0.12 0.3467 Study estimates the lifetime benefit of combination therapy in patients with kidney disease without diabetes - EurekAlert 11/22/2022, 21:00:43
XNCR Xencor Inc 0.12 1.065 Boston Scientific snatches up gastro-focused Apollo Endosurgery for $615M - FierceBiotech 11/29/2022, 12:54:14
XNCR Xencor Inc 0.12 1.065 Full-Life wants more, acquires New Jersey biotech in efforts to dominate radiopharmaceutical R&D - FierceBiotech 11/29/2022, 11:14:15
XNCR Xencor Inc 0.12 1.065 Philips unveils AI to improve diagnoses from imaging scans - FierceBiotech 11/29/2022, 10:50:33
XNCR Xencor Inc 0.12 1.065 Almirall signs on for European clinical trial project to collect data for patients - FierceBiotech 11/29/2022, 10:36:01
XNCR Xencor Inc 0.12 1.065 Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal - FierceBiotech 11/29/2022, 08:24:27
CRNX Crinetics Pharmaceuticals Inc 0.12 4.2278 Boston Scientific snatches up gastro-focused Apollo Endosurgery for $615M - FierceBiotech 11/29/2022, 12:54:14
CRNX Crinetics Pharmaceuticals Inc 0.12 4.2278 Almirall signs on for European clinical trial project to collect data for patients - FierceBiotech 11/29/2022, 10:36:01
CRNX Crinetics Pharmaceuticals Inc 0.12 4.2278 BigHat, cherry-picking opportunities amid stormy market, pens pact with Merck & Co. - FierceBiotech 11/29/2022, 08:05:06
CRNX Crinetics Pharmaceuticals Inc 0.12 4.2278 AstraZeneca inks $200M solid tumor TCR cell therapy buyout - FierceBiotech 11/29/2022, 06:40:00
CRNX Crinetics Pharmaceuticals Inc 0.12 4.2278 Spearing a sphere of MYC proteins could kill cancer cells - FierceBiotech 11/28/2022, 17:34:45
SAGE Sage Therapeutics Inc 0.12 1.4768 IntegriChain Distribution Experts to Speak at Informa Trade & Channel Strategies - El Paso Inc. 11/29/2022, 08:28:21
SAGE Sage Therapeutics Inc 0.12 1.4768 Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat 11/29/2022, 01:46:05
SAGE Sage Therapeutics Inc 0.12 1.4768 Postpartum Depression Drug Market to Reflect Steady Growth Rate by 2028 Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited. - Digital Journal 11/24/2022, 02:39:21
SAGE Sage Therapeutics Inc 0.12 1.4768 Gene therapy Hemgenix gains FDA clearance for hemophilia B - BioWorld Online 11/23/2022, 13:16:02
SAGE Sage Therapeutics Inc 0.12 1.4768 Alzheimer's Disease Pharmaceutical and Healthcare Latest Pipeline Guide - openPR 11/23/2022, 10:56:00
BPMC Blueprint Medicines Corp 0.12 -2.83 Mackenzie Financial Corp Raises Position in Blueprint Medicines Co. (NASDAQ:BPMC) - ETF Daily News 11/29/2022, 04:44:21
BPMC Blueprint Medicines Corp 0.12 -2.83 Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM - Nasdaq 11/23/2022, 10:51:00
BPMC Blueprint Medicines Corp 0.12 -2.83 Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Rating of "Hold" from Analysts - MarketBeat 11/22/2022, 01:15:09
BPMC Blueprint Medicines Corp 0.12 -2.83 Is Blueprint Medicines Corp (BPMC) Stock a Smart Investment Monday? - InvestorsObserver 11/21/2022, 13:12:27
BPMC Blueprint Medicines Corp 0.12 -2.83 Add Up The Parts: ESGV Could Be Worth $81 - Nasdaq 11/18/2022, 03:00:00
NRIX Nurix Therapeutics Inc 0.12 3.348 Til Therapy Market May Set New Growth Story Nurix Therapeutics, Achilles Therapeutics, Intima Bioscience - Digital Journal 11/28/2022, 07:32:06
NRIX Nurix Therapeutics Inc 0.12 3.348 We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate - Simply Wall St 11/28/2022, 05:20:48
NRIX Nurix Therapeutics Inc 0.12 3.348 Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in - GlobeNewswire 11/10/2022, 03:00:00
NRIX Nurix Therapeutics Inc 0.12 3.348 Cathie Wood's ARKK ETF Heads for Best Day Ever as Risk Assets Surge - Bloomberg 11/10/2022, 03:00:00
NRIX Nurix Therapeutics Inc 0.12 3.348 Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire 11/03/2022, 03:00:00
KYMR Kymera Therapeutics Inc 0.12 3.4394 Captor Therapeutics Reports Q3 2022 Results and Provides Business Update - GlobeNewswire 11/25/2022, 08:00:00
KYMR Kymera Therapeutics Inc 0.12 3.4394 Does Kymera Therapeutics Inc (KYMR) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver 11/23/2022, 15:37:17
KYMR Kymera Therapeutics Inc 0.12 3.4394 Kymera Therapeutics (KYMR) Shares Cross Below 200 DMA - Nasdaq 11/22/2022, 12:52:00
KYMR Kymera Therapeutics Inc 0.12 3.4394 Eczema Therapeutics Market Size to Grow by USD 4.36 Billion, 42% of the Market Growth to Originate from North America - Technavio - PR Newswire 11/22/2022, 11:00:00
KYMR Kymera Therapeutics Inc 0.12 3.4394 Merck Plans To 'Tuck In' Imago And Its Phase III-Ready Hematologic Candidate - Scrip 11/21/2022, 18:03:44
AXSM Axsome Therapeutics Inc 0.12 -5.004 Company Innovation Scorecard - Ranking 3500 Innovative Companies on Activity, Impact and Disruptive Potential of their Intellectual Property (IP) Portfolio - ResearchAndMarkets.com - Business Wire 11/29/2022, 11:27:00
AXSM Axsome Therapeutics Inc 0.12 -5.004 Second Recipient Of Eisai/Biogen Alzheimer's Trial Treatment Dies - Kaiser Health News 11/29/2022, 08:54:06
AXSM Axsome Therapeutics Inc 0.12 -5.004 FedEx To Rally Over 25%? Here Are 10 Other Price Target Changes For Tuesday - CinCor Pharma (NASDAQ:CINC) - Benzinga 11/29/2022, 07:24:15
AXSM Axsome Therapeutics Inc 0.12 -5.004 Five things for pharma marketers to know: Tuesday, November 29, 2022 - MM+M Online 11/29/2022, 05:01:27
AXSM Axsome Therapeutics Inc 0.12 -5.004 Tesla, Apple, Anavex, Axsome, Pinduoduo: Why These 5 Stocks Are Drawing Investors' Attention Today - Appl - Benzinga 11/28/2022, 20:02:36
ARWR Arrowhead Pharmaceuticals Inc. 0.12 7.4643 Amazon touts new data, security services to win cloud business - Yahoo Finance 11/29/2022, 13:03:05
ARWR Arrowhead Pharmaceuticals Inc. 0.12 7.4643 Boston Scientific snatches up gastro-focused Apollo Endosurgery for $615M - FierceBiotech 11/29/2022, 12:54:14
ARWR Arrowhead Pharmaceuticals Inc. 0.12 7.4643 Almirall signs on for European clinical trial project to collect data for patients - FierceBiotech 11/29/2022, 10:36:01
ARWR Arrowhead Pharmaceuticals Inc. 0.12 7.4643 Increasing dental disorders worldwide are expected to proliferate the Dental Implant Abutment Systems Market CAGR: ~7% UnivDatos Market Insights - Yahoo Finance 11/29/2022, 10:30:00
ARWR Arrowhead Pharmaceuticals Inc. 0.12 7.4643 Medicinal Chemistry for Drug Discovery Market to Observe Utmost Growth of USD 12,173.97 Million by 2029, Size, Share, Trends, Key Drivers, Development Trends and Industry Growth Outlook - Yahoo Finance 11/29/2022, 09:30:00
TVTX Travere Therapeutics Inc 0.12 -0.1052 Proteinuria Therapeutics Market Present Scenario and the Growth Prospects 2022 – 2028 GlaxoSmithKline plc - EIN News 11/29/2022, 07:09:00
TVTX Travere Therapeutics Inc 0.12 -0.1052 JPMorgan Chase & Co. Grows Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Armenian Reporter 11/29/2022, 04:50:13
TVTX Travere Therapeutics Inc 0.12 -0.1052 Head to Head Survey: Minerva Neurosciences (NASDAQ:NERV) and Travere Therapeutics (NASDAQ:TVTX) - ETF Daily News 11/29/2022, 01:18:55
TVTX Travere Therapeutics Inc 0.12 -0.1052 Alport Syndrome Therapeutic Pipeline Analysis, 2022 Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Players - Digital Journal 11/28/2022, 21:33:35
TVTX Travere Therapeutics Inc 0.12 -0.1052 Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously - Business Wire India 11/25/2022, 01:37:01
TWST Twist Bioscience Corp 0.12 -1.7572 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Twist Bioscience (TWST) Investors with Significant Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations - GuruFocus.com 11/29/2022, 18:01:50
TWST Twist Bioscience Corp 0.12 -1.7572 Synthetic Biology Market is anticipated to expand at a CAGR of 19.2% from 2023 to 2032 insightSLIC - PharmiWeb.com 11/29/2022, 10:21:24
TWST Twist Bioscience Corp 0.12 -1.7572 Global NGS Kits Market to Reach $26.05 Billion by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research - PR Newswire 11/29/2022, 10:00:00
TWST Twist Bioscience Corp 0.12 -1.7572 North America DNA Digital Data Storage Market to Garner US$ 770.93 Mn by 2028 12.6% CAGR - Impact of COVID-1 - openPR 11/29/2022, 07:58:00
TWST Twist Bioscience Corp 0.12 -1.7572 Global Oligonucleotide Synthesis Global Market Report 2022: Featuring Agilent Technologies, CSBIO, Danaher, Kaneka & More - Yahoo Finance UK 11/29/2022, 04:53:00
CDNA Caredx Inc 0.12 2.8249 Should You Buy CareDx Inc (CDNA) Stock After it Is Down 4.12% in a Week? - InvestorsObserver 11/28/2022, 14:05:02
CDNA Caredx Inc 0.12 2.8249 Transplant Diagnostics Market By Product Type, Application, Size and is expected to reach a value of USD 10,13 - openPR 11/27/2022, 23:04:00
CDNA Caredx Inc 0.12 2.8249 CAREDX, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/23/2022, 16:04:05
CDNA Caredx Inc 0.12 2.8249 CDNA LAWSUIT ALERT: Levi & Kor - GuruFocus.com 11/22/2022, 12:57:10
CDNA Caredx Inc 0.12 2.8249 ROSEN, TOP RANKED INVESTOR COU - GuruFocus.com 11/21/2022, 13:55:57
HALO Halozyme Therapeutics Inc. 0.12 1.0271 Hyaluronidase Market Size to reach a revised size of US$ 2390.00 Mn by 2030 CAGR 12.0% - openPR 11/29/2022, 07:46:00
HALO Halozyme Therapeutics Inc. 0.12 1.0271 Halozyme Therapeutics, Inc. (HALO) Stock: How Does it Score on Fundamental Metrics? - InvestorsObserver 11/28/2022, 15:51:02
HALO Halozyme Therapeutics Inc. 0.12 1.0271 SPDR S&P Biotech ETF Experiences Big Outflow - Nasdaq 11/28/2022, 10:47:00
HALO Halozyme Therapeutics Inc. 0.12 1.0271 11 Best Diabetes Stocks To Buy Now - Yahoo Finance 11/27/2022, 17:27:45
HALO Halozyme Therapeutics Inc. 0.12 1.0271 Auto-Injectors Market Is Estimated to Grow At CAGR of 16.60%, 2022-2030 Latest Industry Coverage By Growth Plus Reports - GlobeNewswire 11/24/2022, 02:23:15
CABA Cabaletta Bio Inc 0.12 8.4507 Will Cabaletta Bio Inc (CABA) Stay at the Top of the Healthcare Sector? - InvestorsObserver 11/29/2022, 13:29:24
CABA Cabaletta Bio Inc 0.12 8.4507 Where Does Cabaletta Bio Inc (CABA) Stock Fall in the Biotechnology Field After It Has Fallen -2.57% This Week? - InvestorsObserver 11/28/2022, 11:51:26
CABA Cabaletta Bio Inc 0.12 8.4507 Cabaletta Bio to Present at th - GuruFocus.com 11/22/2022, 08:08:08
CABA Cabaletta Bio Inc 0.12 8.4507 Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference - The Bakersfield Californian 11/22/2022, 08:02:59
CABA Cabaletta Bio Inc 0.12 8.4507 Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year? - Nasdaq 11/21/2022, 09:40:00
PSTX Poseida Therapeutics Inc 0.12 9.0686 Is Poseida Therapeutics Inc (PSTX) a Bad Choice in Biotechnology Tuesday? - InvestorsObserver 11/29/2022, 11:57:26
PSTX Poseida Therapeutics Inc 0.12 9.0686 Human Gene Therapy Market by Product Type (Non-viral Vectors, Viral Vectors), Application (Neurological Diseases, Cancer, DMD (Duchenne Muscular Dystrophy), Hepatological Diseases, Others), and Geography – Global Trends & Forecasts to 2019- - Skegness Siren 11/27/2022, 02:26:08
PSTX Poseida Therapeutics Inc 0.12 9.0686 AAV Vectors in Gene Therapy - Pipeline Insight, 2022 - ResearchAndMarkets.com - Business Wire 11/22/2022, 11:59:00
PSTX Poseida Therapeutics Inc 0.12 9.0686 Should You Add Poseida Therapeutics Inc (PSTX) Stock to Your Portfolio Monday? - InvestorsObserver 11/21/2022, 12:59:31
PSTX Poseida Therapeutics Inc 0.12 9.0686 Poseida Therapeutics: Early Stage CAR-T Developer Seeing Big Pharma Interest (NASDAQ:PSTX) - Seeking Alpha 11/18/2022, 03:32:00
IKNA Ikena Oncology Inc 0.46 0.4132 Bristol Myers scraps gene therapy deal with uniQure for cardiovascular diseases - Endpoints News 11/29/2022, 11:00:00
IKNA Ikena Oncology Inc 0.46 0.4132 Credit Suisse Adjusts Ikena Oncology's Price Target to $16 From $18, Keeps Outperform Rating - Marketscreener.com 11/29/2022, 09:35:02
IKNA Ikena Oncology Inc 0.46 0.4132 With ops spanning Belgium and China, Full-Life inks $245M buyout to beef up radiopharma pipeline - Endpoints News 11/29/2022, 06:32:00
IKNA Ikena Oncology Inc 0.46 0.4132 Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update - Yahoo Finance 11/28/2022, 08:00:00
IKNA Ikena Oncology Inc 0.46 0.4132 This Type Of Home Took Nearly 30% Of All Home Sales In The Third Quarter - Yahoo Finance 11/25/2022, 12:34:31
MTEM Molecular Templates Inc 0.12 -13.4454 Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference - GlobeNewswire 11/23/2022, 16:30:00
MTEM Molecular Templates Inc 0.12 -13.4454 Reactive granulopoiesis depends on T-cell production of IL-17A and neutropenia-associated alteration of gut microbiota Proceedings of the National Academy of Sciences - pnas.org 11/21/2022, 17:20:35
MTEM Molecular Templates Inc 0.12 -13.4454 What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates - Simply Wall St 11/16/2022, 03:00:00
MTEM Molecular Templates Inc 0.12 -13.4454 7 Dallas-Area Companies Make Deloitte's 2022 Technology Fast 500 List - dallasinnovates.com 11/16/2022, 03:00:00
MTEM Molecular Templates Inc 0.12 -13.4454 Immunogenicity and antigenicity of a conserved fragment of the rhoptry-associated membrane antigen of Plasmodium vivax - Parasites & Vectors - Parasites & Vectors 11/15/2022, 03:00:00
ALPN Alpine Immune Sciences Inc 0.12 -2.6772 Alpine Immune Sciences, Inc. Expected to Post FY2022 Earnings of ($1.58) Per Share (NASDAQ:ALPN) - MarketBeat 11/23/2022, 06:33:25
ALPN Alpine Immune Sciences Inc 0.12 -2.6772 Ancient oral microbiomes support gradual Neolithic dietary shifts towards agriculture - Nature.com 11/22/2022, 11:04:14
ALPN Alpine Immune Sciences Inc 0.12 -2.6772 Alpine Immune Sciences (NASDAQ:ALPN) Now Covered by SVB Leerink - MarketBeat 11/21/2022, 08:34:24
ALPN Alpine Immune Sciences Inc 0.12 -2.6772 Uveitis - Drug Pipeline Landscape, 2022 - openPR 11/17/2022, 03:00:00
ALPN Alpine Immune Sciences Inc 0.12 -2.6772 Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results - Yahoo Finance 11/14/2022, 03:00:00
NVTA Invitae Corp 0.46 1.1494 Invitae Corp (NVTA) Stock Is Down -8.00% This Week: Buy, Hold, or Sell? - InvestorsObserver 11/25/2022, 10:31:47
NVTA Invitae Corp 0.46 1.1494 Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday By Benzinga - Investing.com UK 11/25/2022, 09:13:00
NVTA Invitae Corp 0.46 1.1494 Why PagSeguro Digital Shares Are Trading Lower By 18%? Here Are 40 Stocks Moving In Wednesday’s Mid-Day S - Benzinga 11/23/2022, 13:27:38
NVTA Invitae Corp 0.46 1.1494 Invitae Corp (NVTA) Stock: What Does the Chart Say Thursday? - InvestorsObserver 11/17/2022, 12:58:41
NVTA Invitae Corp 0.46 1.1494 The Global Direct-To-Consumer Genetic Testing Market is expected to grow by $1.26 bn during 2022-2026, accelerating at a CAGR of 13.36% during the forecast period - Yahoo Finance 11/17/2022, 03:00:00
KZR Kezar Life Sciences Inc 0.12 -2.4324 The Lupus Nephritis Market to Climb Swiftly at a Significant CAGR of 8.4% by 2032 DelveInsight - Digital Journal 11/29/2022, 03:59:44
KZR Kezar Life Sciences Inc 0.12 -2.4324 Pyruvate kinase (PK) deficiency Market is going to hit at a CAGR of 5.20% by 2028 - Digital Journal 11/22/2022, 05:56:36
KZR Kezar Life Sciences Inc 0.12 -2.4324 Polymyositis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mecha - openPR 11/22/2022, 04:52:00
KZR Kezar Life Sciences Inc 0.12 -2.4324 KZR-540 blocks PD-1 expression and inhibits tumor growth in vivo - BioWorld Online 11/18/2022, 09:00:00
KZR Kezar Life Sciences Inc 0.12 -2.4324 Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Hold (KZR) - Seeking Alpha 11/16/2022, 03:00:00
MRNA Moderna Inc 0.08 -1.2715 Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch 11/29/2022, 17:32:00
MRNA Moderna Inc 0.08 -1.2715 Moderna Inc. stock falls Tuesday, underperforms market - MarketWatch 11/29/2022, 16:32:00
MRNA Moderna Inc 0.08 -1.2715 What to Watch in the Day Ahead - Wednesday, November 30 - Kalkine Media 11/29/2022, 16:16:32
MRNA Moderna Inc 0.08 -1.2715 Moderna And Pfizer's MRNA Patent Cases Consolidated - Law360 11/29/2022, 14:56:00
MRNA Moderna Inc 0.08 -1.2715 Hustlers Fund to be launched on Wednesday - The Standard 11/29/2022, 12:03:20
SRPT Sarepta Therapeutics Inc 0.05 -3.4877 Should You Add Sarepta Therapeutics Inc (SRPT) Stock to Your Portfolio Tuesday? - InvestorsObserver 11/29/2022, 12:48:23
SRPT Sarepta Therapeutics Inc 0.05 -3.4877 Gene therapy R&D market is projected to grow at a CAGR of 30.1% by 2032: Visiongain Reports Ltd - Benzinga 11/29/2022, 12:29:07
SRPT Sarepta Therapeutics Inc 0.05 -3.4877 Astrazeneca paying up to $320M to acquire individualized TCR T-cell therapy developer Neogene - BioWorld Online 11/29/2022, 12:00:00
SRPT Sarepta Therapeutics Inc 0.05 -3.4877 Notable Monday Option Activity: SRPT, WDAY, CSTM - Nasdaq 11/28/2022, 15:41:00
SRPT Sarepta Therapeutics Inc 0.05 -3.4877 CTLT stock spikes as Barclays says FDA cleared site violations (NYSE:CTLT) - Seeking Alpha 11/28/2022, 14:40:00
MGTA Magenta Therapeutics Inc 0.01 -8.7719 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:35:00
MGTA Magenta Therapeutics Inc 0.01 -8.7719 Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease - FierceBiotech 11/28/2022, 11:20:00
MGTA Magenta Therapeutics Inc 0.01 -8.7719 Sanofi-backed Escient scores $120M series C for neuro-inflammatory pipeline - FierceBiotech 11/28/2022, 11:06:00
MGTA Magenta Therapeutics Inc 0.01 -8.7719 Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal - FierceBiotech 11/28/2022, 10:53:00
MGTA Magenta Therapeutics Inc 0.01 -8.7719 The future of Alzheimer's disease research needs solutions that benefit trial patients - FierceBiotech 11/28/2022, 03:00:00
RVMD Revolution Medicines Inc 0.01 5.2045 Lebanese troops called in to halt drug turf war - Arab News 11/29/2022, 12:31:13
RVMD Revolution Medicines Inc 0.01 5.2045 Brothers among 5 Palestinians killed in West Bank - Arab News 11/29/2022, 11:38:49
RVMD Revolution Medicines Inc 0.01 5.2045 Investors are poised to add Revolution Medicines Inc. (RVMD) Stock to their long term portfolios - MZP News 11/29/2022, 11:24:00
RVMD Revolution Medicines Inc 0.01 5.2045 IRGC threatens Iranian footballers' families ahead of US match - Arab News 11/29/2022, 07:23:50
RVMD Revolution Medicines Inc 0.01 5.2045 Form 6-K ASTRAZENECA PLC For: Nov 29 - StreetInsider.com 11/29/2022, 06:52:07
OLK Olink Holding AB (publ) - ADR 0.05 2.9412 Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year? - Nasdaq 11/29/2022, 09:40:00
OLK Olink Holding AB (publ) - ADR 0.05 2.9412 Zacks.com featured highlights MacroGenics, Olink Holding, NerdWallet, LiveRamp and LivePerson - Yahoo Finance 11/18/2022, 03:00:00
OLK Olink Holding AB (publ) - ADR 0.05 2.9412 Olink Holding AB publ Sponsored ADR (OLK) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq 11/10/2022, 03:00:00
OLK Olink Holding AB (publ) - ADR 0.05 2.9412 Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq 11/08/2022, 03:00:00
NLTX Neoleukin Therapeutics Inc 0.01 11.4553 Layoff Tracker 2022: Spectrum, Tricida, Pear Therapeutics and More Cull Staff BioSpace - BioSpace 11/29/2022, 11:02:44
NLTX Neoleukin Therapeutics Inc 0.01 11.4553 Elizabeth Holmes gets 11 years for Theranos fraud - FierceBiotech 11/28/2022, 18:51:35
NLTX Neoleukin Therapeutics Inc 0.01 11.4553 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:35:00
NLTX Neoleukin Therapeutics Inc 0.01 11.4553 Sanofi-backed Escient scores $120M series C for neuro-inflammatory pipeline - FierceBiotech 11/28/2022, 11:06:00
NLTX Neoleukin Therapeutics Inc 0.01 11.4553 Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal - FierceBiotech 11/28/2022, 10:53:00
GBIO Generation Bio Co 0.01 -3.3028 Early diagnosis for dementia – a blood test may help - CNA 11/29/2022, 18:00:00
GBIO Generation Bio Co 0.01 -3.3028 Dermavant launches first streaming commercial for Vtama - FiercePharma 11/29/2022, 15:20:00
GBIO Generation Bio Co 0.01 -3.3028 Delaware, get ready to vote: Meet your nominees for the 2022 Technical.ly Awards - Technical.ly 11/29/2022, 13:19:26
GBIO Generation Bio Co 0.01 -3.3028 Gene therapy R&D market is projected to grow at a CAGR of 30.1% by 2032: Visiongain Reports Ltd - Benzinga 11/29/2022, 12:29:07
GBIO Generation Bio Co 0.01 -3.3028 Toby Keith Hopes to Get Back to Performing After 'Debilitating' Cancer Battle - kdhlradio.com 11/29/2022, 12:27:32
BCAB BioAtla Inc 0.05 5.6853 Head and Neck Cancer pipeline analysis, FDA Approved drugs, Molecule type, Clinical trials and Emerging therapies by DelveInsight Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche - Digital Journal 11/28/2022, 17:50:46
BCAB BioAtla Inc 0.05 5.6853 BioAtla, Inc. (NASDAQ:BCAB) Director Acquires $16540.00 in Stock - MarketBeat 11/23/2022, 18:43:25
BCAB BioAtla Inc 0.05 5.6853 DelveInsight Evaluates a Robust Osteosarcoma Pipeline as 30+ Influential Pharma Players to Set Foot in the Domain - Yahoo Finance 11/21/2022, 13:00:00
BCAB BioAtla Inc 0.05 5.6853 CAR-T Cell Therapy Treatment Market, Share, Size, Worth USD 37423.56 Million at a CAGR of 30% During the Forecast Period 2028 - Digital Journal 11/21/2022, 06:27:40
BCAB BioAtla Inc 0.05 5.6853 CTOS 2022 Annual Meeting: A Phase 1/2 Study of CFT8634 Trial-in-Progress Poster - Marketscreener.com 11/18/2022, 09:29:08
WVE Wave Life Sciences Ltd. 0.01 -8.5011 The Promise of RNA-Based Therapies - AccessWire 11/29/2022, 13:38:44
WVE Wave Life Sciences Ltd. 0.01 -8.5011 How Strong Is Your Data Balance Sheet? - Knowledge at Wharton - [email protected] 11/29/2022, 12:42:03
WVE Wave Life Sciences Ltd. 0.01 -8.5011 Relax, a Little Stress Might Be Good for You - Port Lavaca Wave 11/29/2022, 10:30:00
WVE Wave Life Sciences Ltd. 0.01 -8.5011 Q&A: Nergis Mavalvala, MIT sciences dean and longtime LIGO physicist - Physics Today 11/29/2022, 10:01:06
WVE Wave Life Sciences Ltd. 0.01 -8.5011 How the Smartphone Is Transforming Medicine - Built In 11/29/2022, 10:00:00
MGNX Macrogenics Inc 0.01 6.1633 Here's How to Find Cheap Stocks Under $10 to Buy for December - Nasdaq 11/29/2022, 12:57:00
MGNX Macrogenics Inc 0.01 6.1633 Should You Buy MacroGenics Inc (MGNX) in Biotechnology Industry? - InvestorsObserver 11/28/2022, 15:58:25
MGNX Macrogenics Inc 0.01 6.1633 Analyst Rating: Will Talkspace Inc (TALK) Stock Outperform the Market? - InvestorsObserver 11/28/2022, 14:52:41
MGNX Macrogenics Inc 0.01 6.1633 Where Does Exagen Inc (XGN) Stock Fall in the Diagnostics & Research Field After It Is Lower By -2.04% This Week? - InvestorsObserver 11/28/2022, 14:52:40
MGNX Macrogenics Inc 0.01 6.1633 Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal - FierceBiotech 11/28/2022, 10:53:00